country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

KM3/BTZ

Definition:

KM3/BTZ is a human Plasma cell-derived cancer cell line and associated with Plasma cell myeloma and Multiple myeloma. KM3/BTZ is a resistant derivative of KM3[Human myeloma] selected against Bortezomib (Velcade. KM3/BTZ is used as an in vitro model of Plasma cell myeloma and Multiple myeloma to investigate apoptosis, cell proliferation, cellular metabolism, drug resistance, and viral infection.

References:

[1]. Wang L, et al. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling. Expert opinion on drug safety. 2024;23(3):277-286.

[2]. Li C, et al. Targeting Glutaminolysis to Treat Multiple Myeloma: An In Vitro Evaluation of Glutaminase Inhibitors Telaglenastat and Epigallocatechin-3-gallate. Anti-cancer agents in medicinal chemistry. 2023;23(7):779-785.

Biomedical Dictionary

The Biomedical Dictionary is a comprehensive and professional collection of biological academic terms and subject datas. All explanations are supported by authoritative books or high impact factor literatures, and you can acquire accurate explanations of the biomedical terms you want to know.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #